Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS
· Delayed Price · Currency is USD
0.282
-0.008 (-2.76%)
Nov 15, 2024, 4:00 PM EST
Northwest Biotherapeutics Employees
Northwest Biotherapeutics had 25 employees as of December 31, 2023. The number of employees increased by 3 or 13.64% compared to the previous year.
Employees
25
Change (1Y)
3
Growth (1Y)
13.64%
Revenue / Employee
$63,840
Profits / Employee
-$2,840,560
Market Cap
365.56M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Sandoz Group AG | 22,633 |
Telix Pharmaceuticals Limited | 234 |
Elekta AB (publ) | 4,718 |
Ryman Healthcare Limited | 7,700 |
Verano Holdings Corp. | 3,900 |
Vireo Growth Inc. | 490 |
Medexus Pharmaceuticals Inc. | 82 |
Northwest Biotherapeutics News
- 4 months ago - Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities - PRNewsWire
- 5 months ago - Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property - PRNewsWire
- 8 months ago - Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors - PRNewsWire
- 10 months ago - Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification - PRNewsWire
- 11 months ago - Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma - PRNewsWire
- 1 year ago - Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application - PRNewsWire
- 1 year ago - Northwest Bio: Another Small Filing Delay - Seeking Alpha
- 1 year ago - Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application - PRNewsWire